MSK Therapeutics Accelerator (Cohort Program)
Biotech & Life Sciences · Run by Memorial Sloan Kettering Cancer Center, Office of Entrepreneurship and Commercialization · New York, NY
Every field is checked against a primary source where we can. How we verify.
The facts
All fields verified Sep 28, 2026- Terms model
- MixedA blend of the models above. Read the terms notes for the specifics.
- Investment
- Not publishedAnnual Cohort Program of Memorial Sloan Kettering's Therapeutics Accelerator, open to startups and to larger biotech and pharmaceutical companies developing cancer therapeutics. Selected companies are matched with an MSK faculty sponsor for one-on-one mentorship, get structured introductions to MSK's translational and clinical facilities, and take part in pitch development, media coaching and in-person pitch showcases, with the aim of defining a co-development workplan and possibly moving into formal Therapeutics Accelerator participation. MSK says it does not provide financial resources through the program; for formal Accelerator partnerships it requests a pre-negotiated commercial stake in the company or co-developed products (equity or royalties), and research budgets are agreed project by project. The 2026 Cohort Program took applications from February 6 to March 30, 2026, kicked off in June 2026 with eight companies, and has its Demo Day in October 2026.
- Equity taken
- Not publishedAnnual Cohort Program of Memorial Sloan Kettering's Therapeutics Accelerator, open to startups and to larger biotech and pharmaceutical companies developing cancer therapeutics. Selected companies are matched with an MSK faculty sponsor for one-on-one mentorship, get structured introductions to MSK's translational and clinical facilities, and take part in pitch development, media coaching and in-person pitch showcases, with the aim of defining a co-development workplan and possibly moving into formal Therapeutics Accelerator participation. MSK says it does not provide financial resources through the program; for formal Accelerator partnerships it requests a pre-negotiated commercial stake in the company or co-developed products (equity or royalties), and research budgets are agreed project by project. The 2026 Cohort Program took applications from February 6 to March 30, 2026, kicked off in June 2026 with eight companies, and has its Demo Day in October 2026.
- Program length
- Not published
- Format
- Not published
- Location
- New York, NY
- Cohorts per year
- 1
- Cohort size
- 8 companies (2026 cohort)
- Stage focus
- startups through established biotech and pharmaceutical companies
- Sub-vertical
- cancer therapeutics, with a special interest in rare cancers
- Demographic focus
- Not published
- Backers
- Memorial Sloan Kettering Cancer Center
- Notable alumni
- Not published
Terms notes: Annual Cohort Program of Memorial Sloan Kettering's Therapeutics Accelerator, open to startups and to larger biotech and pharmaceutical companies developing cancer therapeutics. Selected companies are matched with an MSK faculty sponsor for one-on-one mentorship, get structured introductions to MSK's translational and clinical facilities, and take part in pitch development, media coaching and in-person pitch showcases, with the aim of defining a co-development workplan and possibly moving into formal Therapeutics Accelerator participation. MSK says it does not provide financial resources through the program; for formal Accelerator partnerships it requests a pre-negotiated commercial stake in the company or co-developed products (equity or royalties), and research budgets are agreed project by project. The 2026 Cohort Program took applications from February 6 to March 30, 2026, kicked off in June 2026 with eight companies, and has its Demo Day in October 2026.
Get Biotech & Life Sciences deadline alerts
One digest a week. Deadline alerts only for verticals you pick. Unsubscribe anytime.
Terms in plain English
MSK's Therapeutics Accelerator does not invest cash; MSK says it provides no financial resources through the program. Its Cohort Program pairs each selected company with an MSK faculty sponsor and opens introductions to MSK's translational and clinical resources, with the goal of agreeing a co-development plan. Companies that move into a formal Accelerator partnership give MSK a pre-negotiated commercial stake in the company or the co-developed product, as equity or royalties, and research budgets are negotiated project by project.
Who this is actually for
Startups and more established biotech or pharmaceutical companies with a cancer therapeutic that could benefit from working directly with MSK scientists and clinicians, particularly for rare cancers. Suited to teams that are prepared to share economics with MSK in exchange for co-development access.
MSK Therapeutics Accelerator (Cohort Program) application deadlines
2027 Cohort Program, expected in early 2027 based on the 2026 round (February 6 to March 30, 2026): Timing expected, exact dates not yet confirmed.
Verified Sep 28, 2026Source
Frequently asked questions
- When is the next MSK Therapeutics Accelerator (Cohort Program) application deadline?
- A specific application window for MSK Therapeutics Accelerator (Cohort Program) is not yet published. Timing is expected but not confirmed.
- How much does MSK Therapeutics Accelerator (Cohort Program) invest?
- MSK Therapeutics Accelerator (Cohort Program) does not publish an investment amount, so we record it as not published.
- How much equity does MSK Therapeutics Accelerator (Cohort Program) take?
- MSK Therapeutics Accelerator (Cohort Program) does not publish the equity it takes, so we record it as not published.
- Where is MSK Therapeutics Accelerator (Cohort Program) located and is it in person?
- MSK Therapeutics Accelerator (Cohort Program) is based in New York, NY.
- Is MSK Therapeutics Accelerator (Cohort Program) still active?
- As of our last check on Sep 28, 2026, MSK Therapeutics Accelerator (Cohort Program) is active.
Compare this program
Put MSK Therapeutics Accelerator (Cohort Program) side by side with up to two others to weigh cash, equity, and timing.
Compare MSK Therapeutics Accelerator (Cohort Program)More like MSK Therapeutics Accelerator (Cohort Program)
Sources
Everything above was checked against these, verified Sep 28, 2026.